T1	PROC 44 91	Estudio de fase III, aleatorizado y doble ciego
T2	CHEM 95 104	ianalumab
T3	CHEM 106 112	VAY736
T4	PROC 123 130	placebo
#1	AnnotatorNotes T4	C0032042; Placebos; Therapeutic or Preventive Procedure
T5	CHEM 150 161	eltrombopag
#2	AnnotatorNotes T5	C1831905; eltrombopag; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T6	LIVB 165 174	pacientes
#3	AnnotatorNotes T6	C0030705; Patients; Patient or Disabled Group
T7	DISO 179 210	trombocitopenia inmune primaria
T8	DISO 212 215	PTI
#4	AnnotatorNotes T8	C0398650; Immune thrombocytopenic purpura; Disease or Syndrome
T9	CHEM 248 258	esteroides
#5	AnnotatorNotes T9	C0038317; Steroids; Organic Chemical · Pharmacologic Substance
T10	PROC 280 327	Estudio de fase III, aleatorizado y doble ciego
T11	CHEM 331 340	ianalumab
T12	CHEM 342 348	VAY736
T13	PROC 359 366	placebo
#6	AnnotatorNotes T13	C0032042; Placebos; Therapeutic or Preventive Procedure
T14	CHEM 386 397	eltrombopag
#7	AnnotatorNotes T14	C1831905; eltrombopag; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T15	LIVB 401 410	pacientes
#8	AnnotatorNotes T15	C0030705; Patients; Patient or Disabled Group
T16	DISO 415 446	trombocitopenia inmune primaria
T17	DISO 448 451	PTI
#9	AnnotatorNotes T17	C0398650; Immune thrombocytopenic purpura; Disease or Syndrome
T18	DISO 503 510	recaída
#10	AnnotatorNotes T18	C2825055; Recurrence (disease attribute); Pathologic Function
T19	PROC 523 551	tratamiento de primera línea
#11	AnnotatorNotes T19	C1708063; First line treatment; Therapeutic or Preventive Procedure
T20	CHEM 556 566	esteroides
#12	AnnotatorNotes T20	C0038317; Steroids; Organic Chemical · Pharmacologic Substance
T21	DISO 591 622	Trombocitopenia inmune primaria
T22	DISO 624 627	PTI
#13	AnnotatorNotes T22	C0398650; Immune thrombocytopenic purpura; Disease or Syndrome
T23	LIVB 658 682	Pacientes de ambos sexos
T24	Age 686 707	18 años de edad o más
T25	PROC 731 755	consentimiento informado
#14	AnnotatorNotes T25	C0567423; Informed consent for procedure; Therapeutic or Preventive Procedure
T26	PROC 780 804	consentimiento informado
#15	AnnotatorNotes T26	C0567423; Informed consent for procedure; Therapeutic or Preventive Procedure
T27	PROC 852 863	diagnóstico
#16	AnnotatorNotes T27	C0011900; Diagnosis; Diagnostic Procedure
T28	DISO 867 879	PTI primaria
T29	DISO 910 917	recaída
#17	AnnotatorNotes T29	C2825055; Recurrence (disease attribute); Pathologic Function
T30	PROC 923 951	tratamiento de primera línea
#18	AnnotatorNotes T30	C1708063; First line treatment; Therapeutic or Preventive Procedure
T31	CHEM 956 972	corticosteroides
#19	AnnotatorNotes T31	C0001617; Adrenal Cortex Hormones; Hormone · Organic Chemical · Pharmacologic Substance
T32	CHEM 975 979	IgIV
#20	AnnotatorNotes T32	C1527233; Recombinant Immune Globulin; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T33	PROC 984 1005	Recuento de plaquetas
T34	PROC 1029 1040	tratamiento
#21	AnnotatorNotes T34	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T35	Spec_cue 1082 1088	Pueden
T36	PROC 1150 1159	protocolo
#22	AnnotatorNotes T36	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T37	LIVB 1188 1197	Pacientes
#23	AnnotatorNotes T37	C0030705; Patients; Patient or Disabled Group
T38	DISO 1202 1205	PTI
#24	AnnotatorNotes T38	C0398650; Immune thrombocytopenic purpura; Disease or Syndrome
T39	PROC 1225 1254	tratamientos de segunda línea
#25	AnnotatorNotes T39	C1710038; Second line treatment; Therapeutic or Preventive Procedure
T40	DISO 1263 1266	PTI
#26	AnnotatorNotes T40	C0398650; Immune thrombocytopenic purpura; Disease or Syndrome
T41	Neg_cue 1272 1274	no
T42	PROC 1279 1290	tratamiento
#27	AnnotatorNotes T42	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T43	Negated 1279 1290	tratamiento
T44	CHEM 1295 1311	corticosteroides
#28	AnnotatorNotes T44	C0001617; Adrenal Cortex Hormones; Hormone · Organic Chemical · Pharmacologic Substance
T45	Negated 1295 1311	corticosteroides
T46	CHEM 1316 1320	IgIV
#29	AnnotatorNotes T46	C1527233; Recombinant Immune Globulin; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T47	Negated 1316 1320	IgIV
T48	PROC 1333 1346	esplenectomía
#30	AnnotatorNotes T48	C0037995; Splenectomy; Therapeutic or Preventive Procedure
T49	LIVB 1379 1388	pacientes
#31	AnnotatorNotes T49	C0030705; Patients; Patient or Disabled Group
T50	CHEM 1405 1453	agonistas de los receptores de la trombopoyetina
T51	CHEM 1455 1461	AR-TPO
T52	Duration 1491 1508	máximo una semana
T53	LIVB 1535 1544	Pacientes
#32	AnnotatorNotes T53	C0030705; Patients; Patient or Disabled Group
T54	DISO 1549 1562	anormalidades
#33	AnnotatorNotes T54	C1704258; Abnormality; Finding
T55	PROC 1589 1607	pruebas analíticas
T56	LIVB 1610 1619	pacientes
#34	AnnotatorNotes T56	C0030705; Patients; Patient or Disabled Group
T57	DISO 1624 1641	síndrome de Evans
#35	AnnotatorNotes T57	C0272126; Evans syndrome; Disease or Syndrome
T58	DISO 1659 1668	citopenia
#36	AnnotatorNotes T58	C0010828; Cytopenia; Pathologic Function
T59	LIVB 1672 1681	Pacientes
#37	AnnotatorNotes T59	C0030705; Patients; Patient or Disabled Group
T60	DISO 1702 1726	trastornos hematológicos
#38	AnnotatorNotes T60	C0018939; Hematological Disease; Disease or Syndrome
T61	DISO 1774 1808	parámetros hematológicos alterados
T62	LIVB 1812 1821	Pacientes
#39	AnnotatorNotes T62	C0030705; Patients; Patient or Disabled Group
T63	DISO 1826 1834	sangrado
#40	AnnotatorNotes T63	C0019080; Hemorrhage; Pathologic Function
T64	Date 1835 1841	actual
T65	DISO 1860 1868	sangrado
#41	AnnotatorNotes T65	C0019080; Hemorrhage; Pathologic Function
T66	Spec_cue 1869 1883	potencialmente
T67	DISO 1884 1890	mortal
T68	LIVB 1894 1903	Pacientes
#42	AnnotatorNotes T68	C0030705; Patients; Patient or Disabled Group
T69	DISO 1908 1944	virus de la inmunodeficiencia humana
T70	DISO 1946 1949	VIH
#43	AnnotatorNotes T70	C0458074; Human immunodeficiency virus (HIV) status; Finding
T71	DISO 1952 1975	virus de la hepatitis C
T72	DISO 1977 1980	VHC
T73	PROC 1983 2023	antígeno de superficie de la hepatitis B
#44	AnnotatorNotes T73	C0201477; Hepatitis B surface antigen measurement; Laboratory Procedure
T74	PROC 2025 2030	HBsAg
#45	AnnotatorNotes T74	C0201477; Hepatitis B surface antigen measurement; Laboratory Procedure
T75	PROC 2033 2082	anticuerpo del núcleo del virus de la hepatitis B
T76	PROC 2084 2089	HBcAB
T77	LIVB 2104 2113	Pacientes
#46	AnnotatorNotes T77	C0030705; Patients; Patient or Disabled Group
T78	Neg_cue 2137 2139	no
T79	Negated 2140 2150	controlada
T80	PROC 2173 2194	tratamiento sistémico
T81	LIVB 2230 2239	Pacientes
#47	AnnotatorNotes T81	C0030705; Patients; Patient or Disabled Group
T82	DISO 2244 2262	deterioro hepático
T83	LIVB 2266 2275	Pacientes
#48	AnnotatorNotes T83	C0030705; Patients; Patient or Disabled Group
T84	DISO 2280 2305	trastornos de coagulación
T85	CHEM 2335 2364	medicamentos antiplaquetarios
T86	CHEM 2367 2382	anticoagulantes
#49	AnnotatorNotes T86	C0003280; Anticoagulants; Pharmacologic Substance
T87	LIVB 2386 2395	Pacientes
#50	AnnotatorNotes T87	C0030705; Patients; Patient or Disabled Group
T88	PHYS 2434 2443	lactancia
#51	AnnotatorNotes T88	C0006147; Breast Feeding; Organism Function | C0022925; Lactation; Organ or Tissue Function
T89	Spec_cue 2444 2450	Pueden
T90	PROC 2512 2521	protocolo
#52	AnnotatorNotes T90	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T91	Date 12 16	2022
T92	PROC 837 844	estudio
T93	LIVB 1073 1079	médico
T94	Speculated 1104 1132	otros criterios de inclusión
T95	DISO 1727 1754	clínicamente significativos
T96	Speculated 1884 1890	mortal
T97	DISO 2118 2127	infección
T98	PHYS 2406 2417	embarazadas
T99	Speculated 2466 2494	otros criterios de exclusión
T100	CHEM 568 575	VAYHIT2
T101	PROC 1522 1531	selección
T102	Route 2185 2194	sistémico
T103	Observation 234 243	fracasado
T104	Observation 474 496	respuesta insuficiente
T105	Observation 817 844	participación en el estudio
T106	Quantifier_or_Qualifier 871 879	primaria
T107	Observation 885 907	respuesta insuficiente
T108	Result_or_Value 1006 1013	<30 G/L
T109	Quantifier_or_Qualifier 1104 1109	otros
T110	CONC 1110 1132	criterios de inclusión
T111	Quantifier_or_Qualifier 1238 1254	de segunda línea
T112	Observation 1549 1562	anormalidades
T113	Observation 1566 1581	interés clínico
T114	Quantifier_or_Qualifier 1727 1754	clínicamente significativos
T115	Result_or_Value 1799 1808	alterados
T116	Result_or_Value 2091 2100	positivos
T117	Quantifier_or_Qualifier 2128 2134	activa
T118	Quantifier_or_Qualifier 2140 2150	controlada
T119	Quantifier_or_Qualifier 2306 2318	concurrentes
T120	Quantifier_or_Qualifier 2466 2471	otros
T121	CONC 2472 2494	criterios de exclusión
T122	Patient 165 174	pacientes
T123	Patient 401 410	pacientes
T124	History_of 523 551	tratamiento de primera línea
T125	History_of 556 566	esteroides
T126	Patient 658 682	Pacientes de ambos sexos
T127	Other 1073 1079	médico
T128	Patient 1188 1197	Pacientes
T129	History_of 1225 1254	tratamientos de segunda línea
T130	History_of 1316 1320	IgIV
T131	History_of 1333 1346	esplenectomía
T132	Patient 1379 1388	pacientes
T133	Patient 1535 1544	Pacientes
T134	Patient 1610 1619	pacientes
T135	Patient 1672 1681	Pacientes
T136	History_of 1702 1726	trastornos hematológicos
T137	Patient 1812 1821	Pacientes
T138	History_of 1860 1868	sangrado
T139	Patient 1894 1903	Pacientes
T140	Patient 2104 2113	Pacientes
T141	Patient 2230 2239	Pacientes
T142	Patient 2266 2275	Pacientes
T143	Patient 2386 2395	Pacientes
